Previous 10 | Next 10 |
2023-09-13 07:59:44 ET More on Rocket Pharma Seeking Alpha’s Quant Rating on Rocket Pharmaceuticals Historical earnings data for Rocket Pharmaceuticals Financial information for Rocket Pharmaceuticals Rocket Pharmaceuticals: Thriving Gene Therapy With ...
2023-09-13 06:12:47 ET More on Rocket Pharmaceuticals Financial information for Rocket Pharmaceuticals Rocket Pharmaceuticals: Thriving Gene Therapy With Multiple Catalysts Biggest stock movers today: Rocket Pharmaceuticals and Granite Ridge Resources For fur...
2023-09-13 05:44:03 ET Related stories Granite Ridge Resources: Attempting To Scale Up Production Granite Ridge Resources, Inc. ( GRNT ) Q2 2023 Earnings Call Transcript Rocket Pharmaceuticals: Thriving Gene Therapy With Multiple Catalysts Granite Ridge R...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, announced today the pricing of an underwritten public offering of (i) 7,...
2023-09-12 16:15:44 ET More on Rocket Pharmaceuticals Seeking Alpha’s Quant Rating on Rocket Pharmaceuticals Historical earnings data for Rocket Pharmaceuticals Financial information for Rocket Pharmaceuticals Rocket Pharmaceuticals: Thriving Gene Ther...
2023-08-10 11:03:25 ET Rocket Pharmaceuticals press release ( NASDAQ: RCKT ): Q2 GAAP EPS of -$0.82 in-line. Cash, cash equivalents and investments as of June 30, 2023, were $307.0 million. For further details see: Rocket Pharmaceuticals GAAP EPS of -$0.82 in-line
Initiating enrollment of two-patient pediatric safety run-in for pivotal single-arm Phase 2 study of RP-A501 (Danon Disease); finalizing primary composite endpoint with FDA to support accelerated approval RP-L201 (LAD-I) BLA submitted to FDA; represents Rocket’s first product filin...
2023-08-03 00:42:25 ET Summary Rocket Pharmaceuticals is developing gene therapies for rare diseases, with positive results and safety profiles from clinical trials. The company's financial performance includes $360 million in cash and investments, with increased expenses and a ne...
2023-07-30 06:20:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Opportunity Fund outperformed the broader market in Q2 2023, with a 16.31% retur...
2023-07-26 07:00:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the healthcare industry. In the quarter ended June 30, 2023, Baron Health Care Fund adva...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
11.34%Change Percent:
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a le...
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...